The Latest Breaking News from BDX

Despite Becton, Dickinson and Company’s underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Becton, Dickinson and Company is set to announce its second-quarter results in the upcoming month, and analysts expect a single-digit growth in earnings.

MedTech giant Becton, Dickinson and Company is expected to unveil its first-quarter results in the upcoming month and analysts expect a notable double-digit growth in earnings.

The healthcare industry is set for growth due to evolving healthcare demands and the rapid evolution of medical technologies. Hence, investors might consider investing in healthcare stocks, Becton, Dickinson and Co. (BDX), Zimmer Biomet Holdings (ZBH), and Embecta (EMBC). Read more….

Becton, Dickinson and Company have underperformed the Dow Jones Industrials Average over the past year, yet Wall Street analysts maintain a bullish outlook on the stock’s prospects.

The medtech market is thriving, thanks to the increasing investments and surging demand for enhanced efficiency. Therefore, investors could benefit from these trends by investing in fundamentally solid medical device stocks Becton, Dickinson and Company (BDX), Medtronic (MDT), and Abbott Laboratories (ABT), which are revolutionizing patient care. Keep reading.

Despite Becton, Dickinson and Company’s underperformance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.

Becton, Dickinson and Company is poised to announce its fourth-quarter results next month, and analysts predict a double-digit growth in the company’s bottom-line figure.

These three companies are top choices for a dividend-growth portfolio.